CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic

The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV, the company's mRNA based COVID-19 vaccine candidate, for the use in Switzerland.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news